Brand name: Liposic
Active ingredient (generic name): Carbomer 980
Manufacturer: Bausch & Lomb (Chauvin)
Importer: Behestan Darou
Pharmacotherapeutic group: Artificial tears
Pharmaceutical form: Eye gel
Pharmacodynamic:
Due to its physical properties, the eye gel binds water and forms a translucent lubricating and wetting film on the surface of the eye.
Pharmacokinetic:
No controlled animal nor human pharmacokinetic studies with this product are available. However, absorption or accumulation in eye tissues can presumably be excluded due to the high molecular weight of carbomer. Clinical studies performed with an essentially similar product have shown that ocular residence time can be assumed to be approximately up to 90 minutes.
Therapeutic indication:
Symptomatic treatment of dry eye syndrome.
Dosage and administration:
Therapy of dry eye conditions requires an individual dosage regimen.
According to the severity and intensity of the symptoms, instill one drop into the conjunctival sac 35 times daily; and approximately 30 minutes before going to bed (otherwise there is a risk of sticky eyelids).
Generally, an ophthalmologist should be consulted when treating keratoconjunctivitis sicca, which normally turns out to be long-term or permanent therapy.
An appropriate drop size is obtained when the tube is held in a vertical position above the eye during instillation.
Hypersensitivity to any component of this product.
Special warnings and precautions for use:
|
Contact lenses should be removed prior to administration, and may be inserted again 30 minutes after Liposic has been instilled. Concomitant ocular medication should be administered 15 minutes prior to instillation of Liposic . No specific studies with Liposic have been performed in children. If the symptoms of the dry eye continue or worsen, treatment should be stopped and an ophthalmologist should be consulted. |
Pharmacokinetic interactions:
None known
Please note:
Liposic may prolong the contact-time of topically applied drugs in ophthalmology. Concomitant ocular medication should be administered 15 minutes prior to instillation of Liposic.
Pregnancy and lactation:
Clinical data regarding the safety of Liposic in human pregnancy or lactation are not available. Preclinical data predict that the risk of Liposic use in human pregnancy or lactation is very low. But due to the lack of clinical data the use of Liposic during pregnancy or lactation cannot be recommended.
Storage temperature: Do not store above 25ºC
Products